Identification of E2F-1/Cyclin A antagonists
S K Sharma1, T M Ramsey, Y N Chen
1Oncology Department, Novartis Institute for Biomedical Research, Summit, NJ 07901, USA. sushil.sharma@pharma.novartis.com
Bioorganic & Medicinal Chemistry Letters
|September 11, 2001
Summary
Researchers developed a novel spirolactam scaffold to create compounds targeting E2F-1/Cyclin A. This work identified potential antagonists for this important biological target.
Area of Science:
- Medicinal Chemistry
- Organic Synthesis
- Molecular Biology
Background:
- The E2F-1/Cyclin A complex plays a crucial role in cell cycle regulation.
- Developing small molecules to inhibit this complex is a key strategy in cancer research.
- Targeting protein-protein interactions with small molecules presents significant challenges.
Purpose of the Study:
- To synthesize a novel (S,S)-[Pro-Leu]-spirolactam scaffold.
- To generate a library of compounds based on the 'ZRXL' motif.
- To identify antagonists of the E2F-1/Cyclin A complex.
Main Methods:
- Rational design and synthesis of a spirolactam scaffold.
- Creation of a biased compound library.
- Evaluation of compounds using an E2F-1/Cyclin A binding assay.
- Structure-activity relationship (SAR) analysis of key amino acid residues.
Main Results:
- A simple and effective synthesis of the (S,S)-[Pro-Leu]-spirolactam scaffold was achieved.
- A library of compounds mimicking the 'ZRXL' motif was synthesized.
- Moderately active E2F-1/Cyclin A antagonists were identified.
- The importance of specific amino acid residues (Phe, Leu, Lys, Arg) in the motif was elucidated.
Conclusions:
- The developed spirolactam scaffold is a promising starting point for developing E2F-1/Cyclin A antagonists.
- The identified compounds show potential for further optimization.
- This study provides valuable insights into the SAR of E2F-1/Cyclin A inhibitors.
Related Concept Videos
01:45Positive Regulator Molecules
To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
01:23Negative Regulator Molecules
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
02:39Positive Regulator Molecules
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...